Methotrexate Pfizer Italia (Methotrexate Sodium)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form needed for DNA and RNA synthesis. By limiting nucleotide production, it slows the proliferation of rapidly dividing cells such as cancer cells and immune cells, and also increases extracellular adenosine, which has anti‑inflammatory effects.

The dose of Methotrexate Pfizer Italia is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment goals. Healthcare providers determine the appropriate amount, frequency and route of administration for each patient.

Methotrexate is classified as teratogenic and is contraindicated in pregnancy because it can cause fetal malformations and loss. Women of child‑bearing potential should use effective contraception. Limited data exist for breastfeeding, and the drug may pass into breast milk, so use is generally discouraged.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Methotrexate shares a folate‑antagonist mechanism with drugs such as pemetrexed and trimetrexate, but it is the most widely used for both autoimmune diseases and certain cancers. Compared with newer agents, methotrexate is less expensive and has a well‑characterized safety profile, though monitoring for toxicity remains essential.

Methotrexate Pfizer Italia should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the vial or ampoule sealed until use and avoid exposure to extreme temperatures or direct sunlight.

The product is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular or intrathecal routes, depending on the clinical indication and physician’s prescription. Administration is performed by qualified healthcare professionals using aseptic technique.

Serious risks include bone‑marrow suppression leading to pancytopenia, severe liver injury or fibrosis, pulmonary toxicity such as interstitial pneumonitis, renal impairment from drug precipitation, and life‑threatening infections due to immunosuppression. Patients should be monitored regularly for these complications.

Methotrexate should be avoided in patients with known hypersensitivity to the drug, severe renal or hepatic impairment, active infections, and in women who are pregnant or planning to become pregnant. Caution is also advised for individuals with pre‑existing lung disease or immunodeficiency.